Abstract
In the early 1970s, soon after the discovery of Fc receptors on lymphocytes, molecules binding antigen-complexed IgG were detected in culture supernatants of mouse activated T cells and called IgG-binding factors (IgG-BF). These IgG-BF were hypothesized to be derived from membrane FcγR and to correspond to soluble forms of these receptors. Soluble forms of Fcγ receptors (sFcγR) were subsequently described in supernatants of cells of the immune system other than T cells and generalized to isotypes other than IgG. The cloning and identification of FcR genes allowed the molecular characterization of some of their soluble products and the demonstration that soluble FcR can be generated either by proteolytic cleavage of membrane FcR or by alternative splicing of TM-encoding exons of FcR genes.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Fridman WH, Golstein P. Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol 1974; 11:442–455.
Néauport-Sautès C, Rabourdin-Combe C, Fridman WH. T cell hybrids bear Fey receptors and secrete suppressor immunoglobulin binding factor. Nature 1979; 277:656–659.
Pure E, Durie CJ, Summerill CK et al. Identification of soluble Fe receptors in mouse serum and the conditioned medium of stimulated B cells. J Exp Med 1984; 160:1836–1849.
Esposito-Farèse ME, Sautès C, de la Salle H et al. Membrane and soluble FcTγRII/III modulate the antigen presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol 1995; 155:1725–1736.
Teillaud J-L, Bouchard C, Astier A et al. Natural and recombinant soluble low-affinity FcγR: detection, purification, and functional activities. Immuno Meth 1994; 4:48–64.
Daëron M, Sautès C, Bonnerot C et al. Murine type II Fey receptors and IgG-binding factors. Chem Immunol 1989; 47:21–78.
Lynch A, Tartour E, Teillaud JL et al. Increased levels of soluble low affinity FcγReceptor (IgG-binding factor) in the sera of tumour-bearing mice. Clin Exp Immunol 1992; 87: 208–214.
Sautès C, Varin N, Teillaud C et al. Soluble Fcγ receptors II (FcγRII) are generated by cleavage of membrane FcγRII. Eur J Immunol 1990; 21:231–234.
Fridman WH, Bonnerot C, Daëron M et al. Structural bases of Fcγ receptor functions. Immunol Rev 1992; 125:49–76.
Tartour E, de la Salle H, de la Salle C et al. Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (FcγR) encoded by an alternatively spliced transcript of the FcγRII gene. Intern Immunol 1993; 5:859–868.
Sautès C, Galinha A, Bouchard C et al. Recombinant soluble Fcγ receptors: production, purification and biological activities. J Chromatography B 1994; 662:197–207.
Varin N, Sautès C, Galinha A et al. Recombinant soluble receptors for the Fcγ portion inhibit antibody production in vitro. Eur J Immunol 1989; 19:2263–2268.
Hindley AS, Gao Y, Nash PH et al. The interaction of IgG with FcγRII: Involvement of the lower hinge binding site as probed by NMR. Bioch Soc Transactions 1993; 21:337S.
Lund J, Pound JD, Jones PT et al. Multiple binding sites on the CH2 domain of IgG mouse FcγRII. Mol Immunol 1992; 29:53–59.
Diamond B, Birshtein BK, Scharff MD. Site of binding of mouse IgG2b to the Fc receptor on mouse macrophages. J Exp Med 1979; 150:721–726.
Sandor M, Galon J, Takacs L et al. An alternative Fcγ-receptor ligand: Potential role in T cell development. Prod Natl Acad Sci USA 1994; 91:12857–12861.
Sarmay G, Rozsnyay Z, Gergely J. FcγRII expression and release on resting and activated human B lymphocytes. Mol Immunol 1990; 27:1195–1200.
Astier A, de la Salle H, de la Salle C et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (FcγRII/CD32) that inhibits the binding of immune-complexes to FcγR+ cells. J Immunol 1994; 152:201–212.
Gachet C, Astier A, de la Salle H et al. Release of FcγRIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant FcγRIIa2. Blood 1995; 85:698–704.
Rappaport EF, Cassel DL, Walterhouse DO et al. A soluble form of the human Fc receptor FcγRIIA: cloning, transcript analysis and detection. Exp Hematol 1993; 21:689.
Teillaud C, Fridman WH, Sautès C. Mise en évidence de récepteurs solubles de type II pour la partie Fc des IgG (ou RFcγIIs) dans la salive totale humaine. J Biol Buccale 1992; 20:3–10.
Astier A, de la Salle H, Moncuit J et al. Detection and quantification of secreted soluble FcγRIIA in human sera by an enzyme-linked immuno-adsorbent assay. J Immunol Methods 1993; 166:1–10.
Sarmay G, Rozsnyay Z, Szabo L et al. Modulation of type II Fcγ receptor expression on activated human B lymphocytes. Eur J Immunol 1991; 21:541–549.
Walterhouse DO, Cassel DL, Schreiber AD et al. Characterization of HEL cell FcγRII cDNA clone lacking the sequence coding for the transmembrane region. Blood 1988; 72:344a.
Warmerdam PAM, Van de Winkel JGJ, Vlug A et al. A single amino acid in the second domain of the human Fcγ Receptor II is critical for human IgG2 binding. J Immunol 1991; 147:1338–1343.
de la Salle C, Esposito-Farèse ME, Bieber T et al. Release of soluble FcγRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion ? J. Investig Dermatol 1992; 99:15s–17s.
de la Salle H, Astier A, Esposito-Farese ME et al. Soluble FcγRII/CD32 released from human Langerhans cells are produced, at least in part, by the secretion of a transmembrane deleted receptor. Arch Derm Res 1993; 285:109.
Huizinga TWJ, de Haas M, van Oers MHJ et al. The plasma concentration of soluble Fc-gamma RIII is related to production of neutrophils. British Journal of Haematology 1994; 87:459–463.
Selvaraj P, Rosse WF, Silber R et al. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333:565–567.
Huizinga TWJ, Kuijpers RWAM, Kleijer M et al. Maternal neutrophil FcRIII deficieny leading to neonatal isoimmune neutropenia. Blood 1990; 76:1927–1932.
Koene HR, de Haas M, Kleijer M et al. NA-phenotype-dependent differences in neutrophils FcγRIIIb expression cause differences in plasma levels of soluble FcγRIII. Br J Haematol 1996; 93:235–241.
de Haas M, Kleijer M, Minchinton RM et al. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994; 152:900–907.
Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. J Immunol 1994; 152:1314–1322.
Huizinga TW, De haas M, Kleijer M et al. Soluble Fey receptor III (CD16) in human plasma originates from release by neutrophils. J Clin Invest 1990; 86:416–423.
Tosi MF, Zakem H. Surface expression of Fcγ Receptor III (CD16) on chemoattractant-stimulated neutrophils is determined by both surface shedding and translocation from intracellular storage compartments. J Clin Invest 1992; 90:462–470.
Müllberg J, Durie FH, Otten-Evans C et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155:5198–5205.
Dransfield I, Buckle AM, Savill JS et al. Neutrophil apoptosis is associated with a reduction in CD16 (FcγRIII) expression. J Immunol 1994; 153:1254–1263.
Homburg CHE, de Haas M, von dem Borne AEGK et al. Human neutrophils lose their surface FcγRIII and acquire annexin V binding sites during apoptosis in vitro. Blood 1995; 2:532–540.
Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release natural killer cell-associated FcγRIII (CD16-II). J Immunol 1991; 147:3459–3465.
Teillaud C, Galon J, Zilber M-T et al. Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen (PWM)-induced responses. Blood 1993; 82:3081–3090.
Galon J, Gauchat JF, Mazières N et al. Soluble Fey Receptor type III (FcγRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol 1996; 157:1184–1192.
Zhou M-J, Todd III RF, van de Winkel JGJ et al. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fcγ receptor III on human neutrophils. J Immunol 1993; 150:3030–3041.
Poo H, Krauss J, Mayo-Bond L et al. Interaction of Fc gamma receptor type IIIB with complement receptor type 3 in fibroblast transfectants: evidence from lateral diffusion and resonance energy transfer studies. J Mol Biol 1995; 247:597–612.
Zhou M, Brown E. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol 1994; 125:1407.
Gisler RH, Fridman WH. Suppression of in vitro antibody synthesis by Immunoglobulin-Binding Factor. J Exp Med 1975; 142:507–511.
Gisler R H, Fridman WH. Inhibition of the in vitro 19S and 7S antibody response by Immunoglobulin- Binding Factor (IBF) from alloantigen-activated T cells. Cell Immunol 1976; 23:99–107.
Teillaud J-L, Amigorena S, Moncuit J et al. Immunoglobulin G-binding factors (IgG-BF) inhibit IgG secretion by, as well as proliferation of, hybridoma B cells. Immunol Letters 1987; 16:139–144.
Lê Thi Bich T, Samarut C, Brochier J et al. Suppression of mitogen-induced peripheral B cell differentiation by soluble Fey receptors released from lymphocytes. Eur J Immunol 1980; 10:894–899.
Bouchard C, Galinha A, Tartour E et al. A transforming growth factor β-like immunosuppressive factor in immunoglobulin G-binding factor. J Exp Med 1995; 182:1717–1726.
Fridman WH, Teillaud J-L, Bouchard C et al. Soluble Fcγ receptors. J Leuk Biol 1993; 54:504–512.
Aarli A, Skeie Jensen T, Ulvestad E et al. Suppression of mitogen-induced lymphoproliferation by soluble IgG Fc receptors in retroplacental serum in normal human pregnancy. Scand. J Immunol 1993; 37:237–243.
Stach RM, Rowley A. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor β and suppresses cytolytic T Cell responses to unrelated alloantigens. J Exp Med 1993; 178:841–852.
Naito K, Hirama M, Okumura K et al. Soluble form of the human high-affinity receptor for IgE inhibits recurrent allergic reaction in a novel mouse model of type I allergy. Eur J Immunol 1995; 25:1631–1637.
Ra C, Kuromitsu S, Hirose T et al. Soluble human high-affinity receptor for IgE abrogates the IgE-mediated allergic reaction. Intern Immunol 1993; 5:47–54.
Ishizaka K. Twenty years with IgE: from the identification of IgE to regulatory factors for the IgE response. J Immunol 1985; 135:1–10.
Ishizaka T, Sterk AR, Daëron M et al. Biochemical analysis of desensitization of mouse mast cells. J Immunol 1985; 135: 492–501.
Kuff EL, Mietz JA, Trounstine ML et al. cDNA clones encoding murine IgE-binding factors represent multiple structural variants of intracisternal A-particle genes. Proc Natl Acad Sci USA 1986; 83:6583–6587.
Moore KW, Jardieu P, A. MJ et al. Rodent IgE-binding factor genes are members of an endogeneous retrovirus-like gene family. J Immunol 1986; 136:4283–4290.
Sarfati M, Nakajima T, Frost H et al. Purification and partial biochemical characterization of IgE-binding factors secreted by a human B lymphoblastoid cell line. Immunology 1987; 60:539–545.
Kikutani H, Inui S, Sato R et al. Molecular structure of human lymphocyte receptor for Immunoglobulin E. Cell 1986; 47:657–665.
Delespesse G, Sarfati M, Hofstetter H. Human IgE-binding factors. Immunol Today 1989; 10:159–164.
Letellier M, Nakajima T, Pulido-Cejudo G et al. Mechanism of formation of human IgE-binding factors (soluble CD23): III. Evidence for a receptor (FcεRII)-associated proteolytic activity. J Exp Med 1990; 172:693–700.
Matsui M, Nunez R, Sachi Y et al. Alternative transcripts of the human isoform in the type-II cell surface receptor. FEBS Letter 1993; 335:51–56.
Beavil A, Edmeades R, Gould H et al. α-Helical coiled-coil stalks in the low-affinity receptor for IgE (FcεRII/CD23) and related C-type lectins. Proc Nad Acad Sci USA 1992; 89:753–760.
Delespesse G, Suter U, Mossalayi D et al. Expression, structure and function of the CD23 antigen. Adv Immunol 1991; 49:149–191.
Bourget I, Di Berardino W, Breittmayer J-P et al. CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (FcεRII/CD23) in human B cells by increasing the extent of its cleavage. Eur J Immunol 1995; 25:1872–1876.
Bonnefoy JY, Defrance T, Peronne C et al. Human recombinant interleukin 4 induces normal B cells to produce soluble CD23/IgE-binding factor analogous to that spontaneously released by lymphoblastoid B cell lines. Eur J Immunol 1988; 18:117–122.
Hashimoto S, Koh K, Tomita Y et al. TNF-α regulates IL-4 induced FcεRII/CD23 gene expression and soluble FcεRII release by human monocytes. Int Immunol 1995; 7:705–713.
Pène J, Rousset F, Brière F et al. Interleukin 5 enhances interleukin 4-in-duced IgE production by normal human B cells. The role of soluble CD23 antigen. Eur J Immunol 1988; 18:929–935.
Bertho J-M, Fourcade C, Dalloul AH et al. Synergistic effect of interleukin 1 and soluble CD23 on the growth of human CD4+ bone marrow-derived T cells. Eur J Immunol 1991; 21:1073–1080.
Mossalayi MD, Arock M, Bertho J-M et al. Proliferation of early human myeloid precursors induced by interleukin-1 and recombinant soluble CD23. Blood 1990; 75:1924–1930.
Mossalayi MD, Lecron J-C, Dalloul AH et al. Soluble CD23 (FcεRII) and interleukin 1 synergistically induce early human thymocyte maturation. J Exp Med 1990; 171:959–964.
Liu Y-J, Cairns JA, Holder MJ et al. Recombinant 25-kDa CD23 and interleukin la promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21:1107–1114.
Aubry J-P, Pochon S, Graber P et al. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358:505–507.
Lecoanet-Henchoz S, Gauchat J, Aubry J et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CDllc-CD18. Immunity 1995; 3:119–125.
Armant M, Rubio M, Delespesse G et al. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J Immunol 1995; 155:4868–4875.
Bartlett C, Conrad DH. Murine soluble FcεRII: A molecule in search of a function. Res Immunol 1992; 152:3378.
Stief A, Texido G, Sansig G et al. Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. J Immunol 1994; 152:3378–3390.
Kehry MR, Yamashita LC. Role of the low-affinity Fcε receptor in B lymphocyte antigen presentation. Res Immunol 1990; 141:77–81.
Fujiwara H, Kikutani H, Suematsu S et al. The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice. Proc Natl Acad Sci USA 1994; 91:6835–6839.
Yu P, Kosco-Vilbois M, Richards M et al. Negative feedback regulation of IgE synthesis by murine CD23. Nature 1994; 369:753–755.
Kiyono H, Mosteller-Barnum LM, Pitts AM et al. Isotype-specific immunoregulation. IgA-binding factors produced by Fcα receptor-positive T cell hybridomas regulate IgA responses. J Exp Med 1985; 161:731–747.
Yodoi J, Adachi M, Teshigawara K et al. T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-Induced formation of suppressive IgA-Binding Factor(s) by a murine T hybridoma bearing FcγR and FcαR. J Immunol 1983; 131:303–310.
Yodoi J, Adachi M, Keisuke T et al. T cell hybridoma co-expressing Fc receptors for different isotypes. I. Reciprocal regulation of FcγR and FcγR expression by IgA and interferon. Immunol 1983; 4:551–559.
Simpson SD, Snider DP, Zettel LA et al. Soluble FcR block suppressor T cell activity at low concentration in vitro allowing isotype-specific antibody production. Cell Immunol 1996; 167:122–128.
Coico RF, Siskind GW, Thorbecke J. Role of IgD and T cells in the regulation of humoral immune response. Immunol. Rev 1988; 105:45–68.
Maliszewski CR, March CJ, Schoenborn MA et al. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990; 172:1665–1672.
Rights and permissions
Copyright information
© 1997 R.G. Landes Company
About this chapter
Cite this chapter
Sautès, C. (1997). Soluble Fc Receptors. In: Cell-Mediated Effects of Immunoglobulins. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1181-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1181-2_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8501-4
Online ISBN: 978-1-4613-1181-2
eBook Packages: Springer Book Archive